Top

Published in:

01-04-2020 | Myasthenia Gravis | Original article

Myositis as a neuromuscular complication of immune checkpoint inhibitors

Authors: Lynn Vermeulen, Christophe E. Depuydt, Petra Weckx, Oliver Bechter, Philip Van Damme, Dietmar R. Thal, Kristl G. Claeys

Published in: Acta Neurologica Belgica | Issue 2/2020

Abstract

Immune checkpoint inhibitors (ICI) induce improved clinical outcomes associated with numerous cancers, but immune-related adverse events can occur, including neuromuscular complications. We searched for all muscle biopsies from the patient data system of University Hospitals Leuven (UZ Leuven) from January 2014 to July 2018 (n = 686) and collected clinical data of patients with a biopsy-proven ICI-related myositis and expanded the pathological examinations. We identified three cases of ICI-related myositis in patients with malignant melanoma. The clinical phenotype ranged from mild to life threatening. Two patients had a myositis–myasthenia gravis overlap syndrome and one had a co-occurring myocarditis. Pathological examination showed a necrotizing and/or inflammatory myopathy with CD4 + and CD8 + T cells and CD68 + macrophages. IgG staining was positive in all cases. PD-1 and PD-L1 reactions were negative for inhibitors of the PD-1/PD-L1 pathway (nivolumab, atezolizumab) and positive for CTLA-4 inhibitors (ipilimumab). With increasing usage of ICI, clinicians must be aware of rare but potentially serious adverse events such as myositis. Early detection by inquiring about complaints and clinical signs of weakness and monitoring the creatine phosphokinase level in serum are recommended. Our histological findings are in line with other reports. The IgG positivity suggests a local role of the ICI in the pathophysiology of the myositis. Further research must be performed to identify patients at risk and to optimize treatment of the complications.

Kreamer KM (2014) Immune checkpoint blockade: a new paradigm in treating advanced cancer. J Adv Pract Oncol 5(6):418–431PubMedPubMedCentral

Chen L, Han X (2015) Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 125(9):3384–3391. https://doi.org/10.1172/JCI80011 CrossRefPubMedPubMedCentral

Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723. https://doi.org/10.1056/NEJMoa1003466 CrossRefPubMedPubMedCentral

Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL (2015) Antagonists of PD-1 and PD-L1 in cancer treatment. Semin Oncol 42(4):587–600. https://doi.org/10.1053/j.seminoncol.2015.05.013 CrossRefPubMedPubMedCentral

Sadreddini S, Baradaran B, Aghebati-Maleki A, Sadreddini S, Shanehbandi D, Fotouhi A, Aghebati-Maleki L (2018) Immune checkpoint blockade opens a new way to cancer immunotherapy. J Cell Physiol. https://doi.org/10.1002/jcp.27816 CrossRefPubMed

Fellner A, Makranz C, Lotem M, Bokstein F, Taliansky A, Rosenberg S, Blumenthal DT, Mandel J, Fichman S, Kogan E, Steiner I, Siegal T, Lossos A, Yust-Katz S (2018) Neurologic complications of immune checkpoint inhibitors. J Neurooncol 137(3):601–609. https://doi.org/10.1007/s11060-018-2752-5 CrossRefPubMed

Kolb NA, Trevino CR, Waheed W, Sobhani F, Landry KK, Thomas AA, Hehir M (2018) Neuromuscular complications of immune checkpoint inhibitor therapy. Muscle Nerve. https://doi.org/10.1002/mus.26070 CrossRefPubMedPubMedCentral

Spain L, Walls G, Julve M, O'Meara K, Schmid T, Kalaitzaki E, Turajlic S, Gore M, Rees J, Larkin J (2017) Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol 28(2):377–385. https://doi.org/10.1093/annonc/mdw558 CrossRefPubMed

Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, Liewluck T, Hammack JE, Sandroni P, Finnes H, Mauermann ML (2017) Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol 74(10):1216–1222. https://doi.org/10.1001/jamaneurol.2017.1912 CrossRefPubMedPubMedCentral

10.

Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, Uhara H, Hasegawa Y, Inomata S, Otani Y, Yokota K, Hirose T, Tanaka R, Suzuki N, Matsui M (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89(11):1127–1134. https://doi.org/10.1212/WNL.0000000000004359 CrossRefPubMed

11.

Touat M, Maisonobe T, Knauss S, Ben Hadj Salem O, Hervier B, Aure K, Szwebel TA, Kramkimel N, Lethrosne C, Bruch JF, Laly P, Cadranel J, Weiss N, Behin A, Allenbach Y, Benveniste O, Lenglet T, Psimaras D, Stenzel W, Leonard-Louis S (2018) Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology 91(10):e985–e994. https://doi.org/10.1212/WNL.0000000000006124 CrossRefPubMed

12.

Moreira A, Loquai C, Pfohler C, Kahler KC, Knauss S, Heppt MV, Gutzmer R, Dimitriou F, Meier F, Mitzel-Rink H, Schuler G, Terheyden P, Thoms KM, Turk M, Dummer R, Zimmer L, Schroder R, Heinzerling L (2019) Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer 106:12–23. https://doi.org/10.1016/j.ejca.2018.09.033 CrossRefPubMed

13.

Hunter G, Voll C, Robinson CA (2009) Autoimmune inflammatory myopathy after treatment with ipilimumab. Can J Neurol Sci 36(4):518–520CrossRef

14.

Kimura T, Fukushima S, Miyashita A, Aoi J, Jinnin M, Kosaka T, Ando Y, Matsukawa M, Inoue H, Kiyotani K, Park JH, Nakamura Y, Ihn H (2016) Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci 107(7):1055–1058. https://doi.org/10.1111/cas.12961 CrossRefPubMedPubMedCentral

15.

Haddox CL, Shenoy N, Shah KK, Kao JC, Jain S, Halfdanarson TR, Wijdicks EF, Goetz MP (2017) Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm. Ann Oncol 28(3):673–675. https://doi.org/10.1093/annonc/mdw655 CrossRefPubMed

16.

Vallet H, Gaillet A, Weiss N, Vanhaecke C, Saheb S, Touitou V, Franck N, Kramkimel N, Borden A, Touat M, Ricard D, Verny M, Maisonobe T, Psimaras D (2016) Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma. Ann Oncol 27(7):1352–1353. https://doi.org/10.1093/annonc/mdw126 CrossRefPubMed

17.

Mitchell EL, Lau PKH, Khoo C, Liew D, Leung J, Liu B, Rischin A, Frauman AG, Kee D, Smith K, Brady B, Rischin D, Gibson A, Mileshkin L, Klein O, Weickhardt A, Arulananda S, Shackleton M, McArthur G, Ostor A, Cebon J, Solomon B, Buchanan RR, Wicks IP, Lo S, Hicks RJ, Sandhu S (2018) Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: a case series. Eur J Cancer 105:88–102. https://doi.org/10.1016/j.ejca.2018.09.027 CrossRefPubMed

18.

De Velasco G, Je Y, Bosse D, Awad MM, Ott PA, Moreira RB, Schutz F, Bellmunt J, Sonpavde GP, Hodi FS, Choueiri TK (2017) Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. Cancer Immunol Res 5(4):312–318. https://doi.org/10.1158/2326-6066.CIR-16-0237 CrossRefPubMedPubMedCentral

19.

Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J, Lebbe C, Belin C, Ursu R, Carpentier AF (2017) Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 73:1–8. https://doi.org/10.1016/j.ejca.2016.12.001 CrossRefPubMed

20.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23–34. https://doi.org/10.1056/NEJMoa1504030 CrossRefPubMedPubMedCentral

21.

Astaras C, de Micheli R, Moura B, Hundsberger T, Hottinger AF (2018) Neurological adverse events associated with immune checkpoint inhibitors: diagnosis and management. Curr Neurol Neurosci Rep 18(1):3. https://doi.org/10.1007/s11910-018-0810-1 CrossRefPubMed

22.

Hottinger AF (2016) Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 29(6):806–812. https://doi.org/10.1097/WCO.0000000000000391 CrossRefPubMed

23.

Liewluck T, Kao JC, Mauermann ML (2018) PD-1 inhibitor-associated myopathies: emerging immune-mediated myopathies. J Immunother 41(4):208–211. https://doi.org/10.1097/CJI.0000000000000196 CrossRefPubMed

24.

Puwanant A, Isfort M, Lacomis D, Zivkovic SA (2018) Clinical spectrum of neuromuscular complications after immune checkpoint inhibition. Neuromuscul Disord. https://doi.org/10.1016/j.nmd.2018.11.012 CrossRefPubMed

25.

Pushkarevskaya A, Neuberger U, Dimitrakopoulou-Strauss A, Enk A, Hassel JC (2017) Severe ocular myositis after ipilimumab treatment for melanoma: a report of 2 cases. J Immunother 40(7):282–285. https://doi.org/10.1097/CJI.0000000000000178 CrossRefPubMed

26.

Lecouflet M, Verschoore M, Giard C, Gohier P, Le Corre Y, Milea D, Martin L (2013) Orbital myositis associated with ipilimumab. Ann Dermatol Venereol 140(6–7):448–451. https://doi.org/10.1016/j.annder.2013.02.029 CrossRefPubMed

27.

Anquetil C, Salem JE, Lebrun-Vignes B, Johnson DB, Mammen AL, Stenzel W, Leonard-Louis S, Benveniste O, Moslehi JJ, Allenbach Y (2018) Immune checkpoint inhibitor-associated myositis. Circulation 138(7):743–745. https://doi.org/10.1161/CIRCULATIONAHA.118.035898 CrossRefPubMed

28.

Shirai T, Sano T, Kamijo F, Saito N, Miyake T, Kodaira M, Katoh N, Nishie K, Okuyama R, Uhara H (2016) Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol 46(1):86–88. https://doi.org/10.1093/jjco/hyv158 CrossRefPubMed

29.

Safa H, Johnson DH, Trinh VA, Rodgers TE, Lin H, Suarez-Almazor ME, Fa'ak F, Saberian C, Yee C, Davies MA, Tummala S, Woodman K, Abdel-Wahab N, Diab A (2019) Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer 7(1):319. https://doi.org/10.1186/s40425-019-0774-y CrossRefPubMedPubMedCentral

30.

Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB (2018) Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391(10124):933. https://doi.org/10.1016/S0140-6736(18)30533-6 CrossRefPubMedPubMedCentral

31.

Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA (2018) National Comprehensive Cancer Network Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36(17):1714–1768. https://doi.org/10.1200/JCO.2017.77.6385 CrossRefPubMedPubMedCentral

32.

Suzuki S, Utsugisawa K, Yoshikawa H, Motomura M, Matsubara S, Yokoyama K, Nagane Y, Maruta T, Satoh T, Sato H, Kuwana M, Suzuki N (2009) Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol 66(11):1334–1338. https://doi.org/10.1001/archneurol.2009.229 CrossRefPubMed

33.

Takamatsu K, Nakane S, Suzuki S, Kosaka T, Fukushima S, Kimura T, Miyashita A, Mukaino A, Yamakawa S, Watanabe K, Jinnin M, Komohara Y, Ihn H, Ando Y (2018) Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia. Ann Clin Transl Neurol 5(11):1421–1427. https://doi.org/10.1002/acn3.654 CrossRefPubMedPubMedCentral

34.

Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu SM, Sharma P (2016) Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer 4:36. https://doi.org/10.1186/s40425-016-0139-8 CrossRefPubMedPubMedCentral

35.

Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Roden DM, Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA Jr, Anders RA, Sosman JA, Moslehi JJ (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375(18):1749–1755. https://doi.org/10.1056/NEJMoa1609214 CrossRefPubMedPubMedCentral

36.

John S, Antonia SJ, Rose TA, Seifert RP, Centeno BA, Wagner AS, Creelan BC (2017) Progressive hypoventilation due to mixed CD8(+) and CD4(+) lymphocytic polymyositis following tremelimumab-durvalumab treatment. J Immunother Cancer 5(1):54. https://doi.org/10.1186/s40425-017-0258-x CrossRefPubMedPubMedCentral

37.

Gandiga PC, Wang AR, Gonzalez-Rivera T, Sreih AG (2018) Pembrolizumab-associated inflammatory myopathy. Rheumatology (Oxford) 57(2):397–398. https://doi.org/10.1093/rheumatology/kex346 CrossRef

38.

Bourgeois-Vionnet J, Joubert B, Bernard E, Sia MA, Pante V, Fabien N, Honnorat J, Streichenberger N (2018) Nivolumab-induced myositis: a case report and a literature review. J Neurol Sci 387:51–53. https://doi.org/10.1016/j.jns.2018.01.030 CrossRefPubMed

39.

Sheik Ali S, Goddard AL, Luke JJ, Donahue H, Todd DJ, Werchniak A, Vleugels RA (2015) Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. JAMA Dermatol 151(2):195–199. https://doi.org/10.1001/jamadermatol.2014.2233 CrossRefPubMed

40.

Coutzac C, Adam J, Soularue E, Collins M, Racine A, Mussini C, Boselli L, Kamsukom N, Mateus C, Charrier M, Cassard L, Planchard D, Ribrag V, Fizazi K, Loriot Y, Lepage P, Scoazec JY, Robert C, Carbonnel F, Chaput N (2017) Colon immune-related adverse events: anti-CTLA-4 and anti-PD-1 blockade induce distinct Immunopathological entities. J Crohns Colitis 11(10):1238–1246. https://doi.org/10.1093/ecco-jcc/jjx081 CrossRefPubMed

41.

Gettings EJ, Hackett CT, Scott TF (2015) Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma. Mult Scler 21(5):670. https://doi.org/10.1177/1352458514549403 CrossRefPubMed

42.

Williams TJ, Benavides DR, Patrice KA, Dalmau JO, de Avila AL, Le DT, Lipson EJ, Probasco JC, Mowry EM (2016) Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 73(8):928–933. https://doi.org/10.1001/jamaneurol.2016.1399 CrossRefPubMed

43.

Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K (2017) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl 4):iv119–iv142. https://doi.org/10.1093/annonc/mdx225 CrossRefPubMed

44.

Simonaggio A, Michot JM, Voisin AL, Le Pavec J, Collins M, Lallart A, Cengizalp G, Vozy A, Laparra A, Varga A, Hollebecque A, Champiat S, Marabelle A, Massard C, Lambotte O (2019) Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2019.1022 CrossRefPubMed

Title: Myositis as a neuromuscular complication of immune checkpoint inhibitors
Authors: Lynn Vermeulen
Christophe E. Depuydt
Petra Weckx
Oliver Bechter
Philip Van Damme
Dietmar R. Thal
Kristl G. Claeys
Publication date: 01-04-2020
Publisher: Springer International Publishing
Keywords: Myasthenia Gravis
Diseases of the neuromuscular synapses and muscles
Checkpoint Inhibitors
Myopathy
Published in: Acta Neurologica Belgica / Issue 2/2020
Print ISSN: 0300-9009
Electronic ISSN: 2240-2993
DOI: https://doi.org/10.1007/s13760-020-01282-w

At a glance: The STEP trials

Springer Medicine

Myositis as a neuromuscular complication of immune checkpoint inhibitors

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2020

Preserved motor skill learning in acute stroke patients

A diagnostic dilemma in the emergency room: intracranial hemorrhages in acute myeloblastic leukemia with hyperleukocytosis

Spontaneous spinal epidural haematoma mimicking acute ischaemic stroke: case report

Neurolisteriosis presenting with acute coma and following near-drowning

An unusual initial presentation of Parkinson’s disease: unilateral standing leg tremor

Early imaging in paraparetic Guillain–Barré syndrome